Enlivex Therapeutics Ltd. Ordinary Shares (ENLV) Dividend History

Enlivex Therapeutics Ltd. is a clinical-stage biotech company specializing in the development of immune rebalancing immunotherapies for the treatment of severe inflammatory and immune-related conditions. Their flagship product pipeline focuses on harnessing the body's immune system to improve outcomes in conditions such as sepsis, graft-versus-host disease, and other immune dysregulation disorders.

Website: https://www.enlivex.com

Dividend History

Enlivex Therapeutics Ltd. Ordinary Shares currently does not pay dividends

Company News

  • Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis

    Enlivex Therapeutics received a notice of allowance for a Japanese patent application covering the use of its Allocetra™ product in treating osteoarthritis, a common and debilitating condition with limited treatment options.

    GlobeNewswire Inc.
  • Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why

    Enlivex (ENLV) plunges after it shares mixed results from a mid-stage study evaluating its lead drug as a potential treatment for sepsis.

    Zacks Investment Research
    Featured Companies: ADMA ANIP LGND
  • Tesla To $180? Here Are 10 Top Analyst Forecasts For Friday

    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Citigroup cut the price target for Starbucks Corporation (NASDAQ: SBUX) from $102 to $95. Citigroup analyst Jon Tower maintained a Neutral rating. Starbucks shares fell 0.1% to close at $85.90 on Thursday. See how other analysts view this stock. Citigroup slashed the price target for Tesla, Inc. (NASDAQ: TSLA) from $196 to $180. Citigroup analyst Itay Michaeli maintained a Neutral rating. Tesla shares gained 1.7% to close at $174.60 on Thursday. See how other analysts view this stock. Needham cut CarMax, Inc. (NYSE: KMX) price target from $99 to $91. Needham analyst Chris Pierce maintained a Buy rating. CarMax shares fell 9.2% to close at $71.98 on Thursday. See how other analysts view this stock. Mizuho cut the price target for Phillips 66 (NYSE: Full story available on Benzinga.com

    Benzinga
    Featured Companies: FAST KMX NFLX PSX SBUX TH TSLA VFC
  • Why Co-Diagnostics Is A Solid Covid-19 Play

    Co-Diagnostics shares rallied after the company posted strong Q2 earnings. TAM is expanding and the stock CODX is trading at too low a market capitalization in the $300M range.

    Seeking Alpha
    Featured Companies: CODX JNJ MRNA NVAX PFE REGN
Page data last updated 07/23/2025 21:34:50 UTC